Clinicoradiological Profile of Lung Cancer
Keywords:
Squamous cell carcinoma ,adenocarcinoma ,Cisplatin , IrinotecanAbstract
Objective:To study clinico-radiological profile of patients of lung cancer and to determine the response to Cisplatin and Irinotecan as chemotherapeutic regimen in appropriately staged IIIB/ IV cases of non small cell lung CancerMethods: All consecutive patients of lung cancer more than 18 years of age were evaluated and staged using standard protocol .All patients with stage III-B and IV non small cell lung cancer were assessed. 20 patients with ECOG score 0, 1 or 2 in the study were enrolled and subjected to chemotherapy regimen .Controls were provided basic supportive care (BSC) including antibiotics, analgesics, bronchodilators and supportive measures.Results:Of 137 patients enrolled the mean age of patients was 57.16 .109 patients (79.6%) were males with Sex Ratio of 3.9:1.The commonest symptom was cough in 109 patients The mean duration of symptom was 5.52 months + SD 6.23. Smoking was found to be present in (85.4%) Majority of the patients were bidi smokers .The commonest sign observed was that of a mass lesion in 78 patients (56.93%) followed by that of collapse .On chest X ray, mass lesion was the most common finding (64.96%) followed by pleural effusion in 40 (29.19) .The commonest paraneoplastic syndrome observed was anorexia in 79 patients (57.66%), cachexia in 63 .Squamous cell carcinoma lung was the commonest histological subtype among male patients (42 out of 96— 43.8%), while adenocarcinoma was the commonest histological subtype among the female patients (10 out of 25-40%)Conclusion:Cisplatin and Irinotecan regimen showed improvement in the median survival and 1 year survival rates (57 weeks and 53% respectively) as compared to basic supportive care. The regimen is cheap; its side effects are mild,tolerable reasonable regimen in resource limited settings.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Deepak Nagar, Kamal Nayan Shringi, Bharat Kumawat

This work is licensed under a Creative Commons Attribution 4.0 International License.